GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMY) » Definitions » EV-to-FCF

NVZMY (Novonesis (Novozymes) B) EV-to-FCF : 96.45 (As of Mar. 25, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Novonesis (Novozymes) B's Enterprise Value is $28,248 Mil. Novonesis (Novozymes) B's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $293 Mil. Therefore, Novonesis (Novozymes) B's EV-to-FCF for today is 96.45.

The historical rank and industry rank for Novonesis (Novozymes) B's EV-to-FCF or its related term are showing as below:

NVZMY' s EV-to-FCF Range Over the Past 10 Years
Min: 25.62   Med: 40.34   Max: 164.82
Current: 97.37

During the past 13 years, the highest EV-to-FCF of Novonesis (Novozymes) B was 164.82. The lowest was 25.62. And the median was 40.34.

NVZMY's EV-to-FCF is ranked worse than
86.77% of 862 companies
in the Chemicals industry
Industry Median: 21.28 vs NVZMY: 97.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-25), Novonesis (Novozymes) B's stock price is $57.56. Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.555. Therefore, Novonesis (Novozymes) B's PE Ratio (TTM) for today is 103.71.


Novonesis (Novozymes) B EV-to-FCF Historical Data

The historical data trend for Novonesis (Novozymes) B's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B EV-to-FCF Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.37 53.41 92.83 52.40 40.75

Novonesis (Novozymes) B Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.15 62.41 52.40 77.08 40.75

Competitive Comparison of Novonesis (Novozymes) B's EV-to-FCF

For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novonesis (Novozymes) B's EV-to-FCF Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Novonesis (Novozymes) B's EV-to-FCF falls into.



Novonesis (Novozymes) B EV-to-FCF Calculation

Novonesis (Novozymes) B's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=28248.062/292.88
=96.45

Novonesis (Novozymes) B's current Enterprise Value is $28,248 Mil.
Novonesis (Novozymes) B's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $293 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novonesis (Novozymes) B  (OTCPK:NVZMY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Novonesis (Novozymes) B's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=57.56/0.555
=103.71

Novonesis (Novozymes) B's share price for today is $57.56.
Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.555.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Novonesis (Novozymes) B EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q2 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q1 2021 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Novonesis AS's Dividend Analysis

By GuruFocus Research 04-30-2024

Half Year 2024 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 08-29-2024